P526 A prediction model for successful increase of adalimumab dose intervals: analysis of the pragmatic open-label randomised controlled non-inferiority LADI trialR Van Linschoten, Frank Hoentjen, R Pauwels et al.|Journal of Crohn s and Colitis|2023Cited by 0